{"schema_version":"secwatch.filing_event.v1","accession":"0001618835-23-000019","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.851339+00:00","generated_at":"2026-06-17T16:40:45.197815+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evofem raises ~$295K via $538K convertible notes & warrants at $0.02/unit","bullets":["Issued $538,461.54 senior subordinate convertible notes (8% interest) and warrants for 26,923,077 common shares at $0.02 exercise price.","Net proceeds to company approx $295,000 after expenses; investors paid ~$650 per $1,000 principal.","Notes convertible at $0.02 per share, mature 3 years from March 20, 2023; warrants expire 5 years from issuance.","Company's stockholders approved reverse stock split on March 15, 2023; shares trade on OTCQB under EVFM.","Registration rights agreement requires filing Form S-1 within set deadlines; potential 2% monthly penalties for registration failures."],"urls":{"canonical":"https://secwatch.observer/filing/0001618835-23-000019","json":"https://secwatch.observer/filing/0001618835-23-000019.json","markdown":"https://secwatch.observer/filing/0001618835-23-000019.md","text":"https://secwatch.observer/filing/0001618835-23-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000019/0001618835-23-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000019/evfm-20230320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T16:40:45.197815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5580c128138b83503bf0d73ac9f01cfb7fdc5a35","claim":"Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at $538,461.54 (effective 2023-03-20).","evidence_excerpt":"On March 20, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $538,461.54 (the “ Notes ”) and warrants (“ Warrants ”) to purchase an aggregate 26,923,077 shares of common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000161883523000019/0001618835-23-000019-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"$538,461.54"},{"label":"Effective","value":"2023-03-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}